The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma
Abstract
Purpose: Radioimmunotherapy (RIT) with yttrium-90 (90 Y)-labeled anti-CD20 antibody (90 Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a high rate of tumor response in patients with relapsed or refractory, low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma (NHL). This study presents the safety data from 349 patients in five studies of outpatient treatment with 90 Y ibritumomab tiuxetan. Patients and Methods: Patients received rituximab 250 mg/m 2 on days 1 and 8, and either 0.4 mCi/kg (15 MBq/kg) or 0.3 mCi/kg (11 MBq/kg) of 90 Y ibritumomab tiuxetan on day 8 (maximum dose, 32 mCi). Patients were observed for up to 4 years after therapy or until progressive disease. Results: Infusion-related toxicities were typically grade 1 or 2 and were associated with rituximab. No significant organ toxicity was noted. Toxicity was primarily hematologic, with nadir counts occurring at 7 to 9 weeks and lasting approximately 1 to 4 weeks depending on the method of calculation. After the 0.4-mCi/kg dose, grade 4 neutropenia, thrombocytopenia, and anemia occurred in 30%, 10%, and 3% of patients, respectively, and after the 0.3-mCi/kg dose, these grade 4 toxicities occurred in 35%, 14%, and 8% of patients, respectively. The risk of hematologic toxicity increased with degree of baseline bone marrow involvement with NHL. Seven percent of patients were hospitalized with infection (3% with neutropenia) and 2% had grade 3 or 4 bleeding events. Myelodysplasia or acute myelogenous leukemia was reported in five patients (1%) 8 to 34 months after treatment. Conclusion: Single-dose 90 Y ibritumomab tiuxetan RIT has an acceptable safety profile in relapsed NHL patients with less than 25% lymphoma marrow involvement, adequate marrow reserve, platelets greater than 100,000 cells/μL, and neutrophils greater than 1,500 cells/μL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Self-citationWitzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
Self-citationKaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3918 · Cited by 584
Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3793 · Cited by 539
Self-citationVose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., & Kaminski, M. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1316 · Cited by 359
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox, S. J., Goris, M. L., Trisler, K. D., Negrin, R. S., Davis, T., Liles, T. M., Grillo-López, A. J., Chinn, P. C., Varns, C., Ning, S., et al. (1996) · PubMed · Cited by 326
Pedersen-Bjergaard, J., Andersen, M. K., & Christiansen, D. H. (2000) · Blood · doi:10.1182/blood.v95.11.3273 · Cited by 245
Wiseman, G. A., White, C. A., Sparks, R. B., Erwin, W. D., Podoloff, D. A., Lamonica, D., Bartlett, N. L., Anthony Parker, J., Dunn, W. L., Spies, S. M., et al. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00107-x · Cited by 183
Self-citationSecond cancers following non-Hodgkin's lymphoma
Travis, L. B., Curtis, R. E., Boice, J. D., Hankey, B. F., & Fraumeni, J. F. (1991) · Cancer · doi:10.1002/1097-0142(19910401)67:7<2002::aid-cncr2820670729>3.0.co;2-e · Cited by 178
Monoclonal antibodies in cancer detection and therapy
Goldenberg, D. M. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90062-t · Cited by 148
Cited by
Non-Hodgkin Lymphoma: Diagnosis and Treatment
Ansell, S. M., & Armitage, J. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1087 · Cited by 356
Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S. J., & Bander, N. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.154 · Cited by 313
Baechler, S., Hobbs, R. F., Jacene, H. A., Bochud, F. O., Wahl, R. L., & Sgouros, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.079947 · Cited by 36
Metadata
- Authors
- Witzig, T. E., White, C. A., Gordon, L. I., Wiseman, G. A., Emmanouilides, C., Murray, J. L., Lister, J., & Multani, P. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-04-01
- Volume
- 21
- Issue
- 7
- Pages
- 1263-1270
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2147581636
- Cited by
- 289
- References
- 11
- FWCI
- 27.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2003.08.043
- The paper
- Witzig, T. E., White, C. A., Gordon, L. I., Wiseman, G. A., Emmanouilides, C., Murray, J. L., Lister, J., & Multani, P. S. (2003). Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.08.043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.